Latest news with #LiquidiaTechnologies
Business Insider
7 days ago
- Business
- Business Insider
Bank of America Securities Sticks to Its Buy Rating for Liquidia Technologies (LQDA)
Bank of America Securities analyst Jason Gerberry reiterated a Buy rating on Liquidia Technologies yesterday and set a price target of $35.00. The company's shares closed yesterday at $24.10. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Gerberry covers the Healthcare sector, focusing on stocks such as Teva Pharmaceutical, Liquidia Technologies, and BioMarin Pharmaceutical. According to TipRanks, Gerberry has an average return of 2.5% and a 48.57% success rate on recommended stocks. In addition to Bank of America Securities, Liquidia Technologies also received a Buy from LifeSci Capital's Cory Jubinville, PhD in a report issued yesterday. However, on July 29, Oppenheimer maintained a Sell rating on Liquidia Technologies (NASDAQ: LQDA). Based on Liquidia Technologies' latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $3.12 million and a GAAP net loss of $38.37 million. In comparison, last year the company earned a revenue of $2.97 million and had a GAAP net loss of $40.93 million
Business Insider
31-05-2025
- Business
- Business Insider
LifeSci Capital Keeps Their Buy Rating on Rocket Pharmaceuticals (RCKT)
LifeSci Capital analyst Cory Jubinville, PhD maintained a Buy rating on Rocket Pharmaceuticals (RCKT – Research Report) today and set a price target of $9.00. Confident Investing Starts Here: Jubinville, PhD covers the Healthcare sector, focusing on stocks such as Liquidia Technologies, Rocket Pharmaceuticals, and Mereo Biopharma Group Plc. According to TipRanks, Jubinville, PhD has an average return of -13.5% and a 29.41% success rate on recommended stocks. In addition to LifeSci Capital, Rocket Pharmaceuticals also received a Buy from Bank of America Securities's Jason Zemansky in a report issued on May 28. However, yesterday, Evercore ISI downgraded Rocket Pharmaceuticals (NASDAQ: RCKT) to a Hold. Based on Rocket Pharmaceuticals' latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $61.33 million. In comparison, last year the company had a GAAP net loss of $62.05 million Based on the recent corporate insider activity of 39 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of RCKT in relation to earlier this year. Earlier this month, John Militello, the VP of Finance, Treasurer, Principal Accounting Officer of RCKT sold 357.00 shares for a total of $2,299.08.
Business Insider
31-05-2025
- Business
- Business Insider
Liquidia Technologies (LQDA) Receives a Buy from LifeSci Capital
In a report released today, Cory Jubinville, PhD from LifeSci Capital maintained a Buy rating on Liquidia Technologies (LQDA – Research Report), with a price target of $41.00. Confident Investing Starts Here: Jubinville, PhD covers the Healthcare sector, focusing on stocks such as Liquidia Technologies, Rocket Pharmaceuticals, and Mereo Biopharma Group Plc. According to TipRanks, Jubinville, PhD has an average return of -13.5% and a 29.41% success rate on recommended stocks. In addition to LifeSci Capital, Liquidia Technologies also received a Buy from H.C. Wainwright's Andrew Fein in a report issued on May 29. However, on May 19, Oppenheimer downgraded Liquidia Technologies (NASDAQ: LQDA) to a Sell.
